Physiological function of tissue factor pathway inhibitor and interaction with heparins

Haemostasis

Volumn 30, Issue SUPPL. 2, 2000, Pages 48-56

  Sandset, Per Morten ^a   Bendz, Bjørn ^a   Hansen, John Bjarne ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Antithrombin; Low molecular weight heparin; Tissue factor pathway inhibitor; Unfractionated heparin

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 7A; DALTEPARIN; ENOXAPARIN; HEPARIN; HEPARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANTICOAGULATION; CARBOXY TERMINAL SEQUENCE; CATALYSIS; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; REBOUND; VASCULAR ENDOTHELIUM;

EID: 0034459007     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054163     Document Type: Conference Paper

References (66)

1. Consequences of tissue factor pathway inhibitor gene-disruption in mice
2. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: Evidence supporting a physiologic role for EPI as a natural anticoagulant
3. Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Shwartzman reaction
4. Tissue factor pathway inhibitor: Potential therapeutic applications
5. Glycosaminoglycans and the regulation of blood coagulation
6. Insight into the mechanism of action of heparin cofactor II
7. Difference in heparin-neutralizing effect of protamine and polybrene as tested by thrombotest
8. Heparin requires both antithrombin and extrinsic pathway inhibitor for its anticoagulant effect in human blood
9. Extrinsic pathway inhibitor (EPI) released to the blood by heparin is a more powerful coagulation inhibitor than is recombinant EPI
10. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI)
11. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains
12. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor
13. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action
14. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: Evidence for a two-step model of inhibition
15. Characterization of human tissue factor pathway inhibitor variants expressed in Saccharomyces cerevisiae
16. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin
17. The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity
18. Tissue factor pathway inhibitor: The carboxy-terminus is required for optimal inhibition of factor Xa
19. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: Evidence that endothelium is the principal site of its synthesis
20. Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture
21. Tissue factor pathway inhibitor (TFPI) - An update
22. Association of tissue factor pathway inhibitor with human umbilical vein endothelial cells
23. The functional expression of tissue factor by fibroblasts and endothelial cells under flow conditions
24. Receptor-mediated endocytosis of coagulation factor Xa requires cell surface-bound tissue factor pathway inhibitor
25. Ligand-induced protease receptor translocation into caveolae: A mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway
26. Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans
27. Binding of tissue factor pathway inhibitor to cultured endothelial cells - Influence of glycosaminoglycans
28. Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins
29. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture
30. Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro
31. Studies of the factor Xa-dependent inhibitor of factor VIIa/tissue factor (extrinsic pathway inhibitor) from cell supernates of cultured human umbilical vein endothelial cells
32. Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators
33. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples
34. Tissue factor pathway inhibitor (TFPI) and its response to heparin in patients with spontaneous deep vein thrombosis
35. The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man
36. Bioavailability and pharmacokinetics of a new low molecular weight heparin (RO-11) - A three way cross-over study in healthy volunteers
37. Low molecular weight heparins: Differences and similarities in approved preparations in the United States
38. A supersulfated low-molecular-weight heparin (IK-SSH) increases plasma levels of free and total tissue factor pathway inhibitor after intravenous and subcutaneous administration in humans
39. The present status of tissue factor pathway inhibitor
40. Fucoidan, as heparin, induces tissue factor pathway inhibitor release from cultured human endothelial cells
41. Effect of depolymerized holothurian glycosaminoglycan (DHG) on tissue factor pathway inhibitor: In vitro and in vivo studies
42. Plasma TFPI activity after intravenous injection of pentasaccharide (PS) and unfractionated heparin in rabbits
43. Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins
44. A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions
45. Measurement of tissue factor pathway inhibitor in normal and postheparin plasma
46. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man
47. Tissue factor pathway inhibitor and anti-FXa kinetic profiles of a new low-molecular-mass heparin, Bemiparin, at therapeutic subcutaneous doses
48. Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins
49. Dose-dependent release of endogenous tissue factor pathway inhibitor by different low molecular weight heparins
50. In vivo characterisation of anti-coagulant and anti-thrombotic activitities of low molecular weight heparins (LMWHs) and unfractionated heparin (UFH)
51. The inhibition of human factor VIIa-tissue factor by antithrombin III-heparin is enhanced by factor X on a human bladder carcinoma cell line
52. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor
53. Kinetics of the inhibition of factor Xa and the tissue factor-factor VIIa complex by the tissue factor pathway inhibitor in the presence and absence of heparin
54. Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: A segment, Gly212-Phe243, of the third Kunitz domain is a heparin-binding site
55. A kinetic analysis of the interaction of human recombinant tissue factor pathway inhibitor with factor Xa utilizing an immunoassay and the effect of antithrombin III/heparin on the complex formation
56. Initiation of the tissue factor pathway of coagulation in the presence of heparin: Control by antithrombin III and tissue factor pathway inhibitor
57. Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa
58. Complex-dependent inhibition of factor VIIa by antithrombin III and heparin
59. Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity
60. Repeated release of the tissue factor pathway inhibitor
61. Loss of heparin-releasable tissue factor pathway inhibitor in patients undergoing PTCA
62. Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: Evidence for a difference in antithrombotic action
63. Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): A possible mechanism for difference in therapeutic efficacy
64. Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: Potential mechanisms for heightened prothrombotic potential
65. Reactivation of unstable angina after the discontinuation of heparin
66. Extrinsic pathway inhibitor - The key to feedback control of blood coagulation initiated by tissue thromboplastin